Date Filed | Type | Description |
08/14/2023 |
4
| Tasse Daniel (CEO) has filed a Form 4 on DBV Technologies S.A.
Txns:
| Granted 764,386 options to buy
@ $0 |
|
06/06/2023 |
4
| Tasse Daniel (Director) has filed a Form 4 on REGENXBIO Inc.
Txns:
| Granted 3,486 shares
@ $0 Granted 17,892 options to buy
@ $19.72, valued at
$352.8k
|
|
06/07/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
11/24/2021 |
4
| Tasse Daniel (CEO) has filed a Form 4 on DBV Technologies S.A.
Txns:
| Granted 274,000 options to buy
@ $0 |
|
06/08/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/11/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
06/02/2020 |
4
| Tasse Daniel (Director) has filed a Form 4 on REGENXBIO Inc.
Txns:
| Granted 10,000 options to buy
@ $37.66, valued at
$376.6k
|
|
06/04/2019 |
4
| Tasse Daniel (Director) has filed a Form 4 on REGENXBIO Inc.
Txns:
| Granted 10,000 options to buy
@ $43.02, valued at
$430.2k
|
|
06/25/2018 |
4
| Tasse Daniel (Director) has filed a Form 4 on Bellerophon Therapeutics, Inc.
Txns:
| Granted 11,987 shares
@ $0 |
|
06/07/2018 |
4
| Tasse Daniel (Director) has filed a Form 4 on Bellerophon Therapeutics, Inc.
Txns:
| Granted 38,216 options to buy
@ $2.27, valued at
$86.8k
|
|
05/30/2018 |
4
| Tasse Daniel (Director) has filed a Form 4 on REGENXBIO Inc.
Txns:
| Granted 12,500 options to buy
@ $49.45, valued at
$618.1k
|
|
09/26/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/30/2017 |
4
| Tasse Daniel (Director) has filed a Form 4 on Bellerophon Therapeutics, Inc.
Txns:
| Granted 25,363 shares
@ $0 |
|
05/26/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
08/16/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
08/16/2016 |
3
| Form 3 - Initial statement of beneficial ownership of securities |
06/21/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
04/29/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |